A client with overactive bladder starts a new prescription for oxybutynin. When assessing the client prior to medication administration, which finding should the practical nurse (PN) report to the charge nurse?

Choice A reason: Peak and trough levels are relevant for drugs like antibiotics, not meloxicam, a nonsteroidal anti-inflammatory drug (NSAID). Meloxicam’s efficacy is assessed clinically, not via blood levels, as it reduces inflammation and pain, making this choice irrelevant for costochondritis management.

Choice B reason: Reassessing pain 30 minutes after meloxicam administration evaluates its effectiveness, as this NSAID inhibits cyclooxygenase, reducing prostaglandin-mediated inflammation and pain in costochondritis. Timely reassessment ensures adequate pain relief, guiding further interventions for breathing discomfort, making this the appropriate intervention.

Choice C reason: Involuntary lip and tongue movements are associated with antipsychotics, not meloxicam. This NSAID does not cause neurological side effects like tardive dyskinesia. Monitoring for this is irrelevant, as meloxicam’s primary concerns are gastrointestinal or renal, not movement disorders.

Choice D reason: Strict intake and output monitoring is unnecessary for meloxicam, which primarily affects inflammation, not fluid balance. While long-term use may impact kidneys, pain reassessment is more immediate for costochondritis, making this choice less relevant than evaluating therapeutic pain relief.

Choice A reason: Iodine allergy is irrelevant to golimumab, a tumor necrosis factor (TNF) inhibitor, as it is not iodine-based. Allergic reactions to biologics are possible but unrelated to iodine sensitivity, making this choice unnecessary for ensuring safe administration of the medication.

Choice B reason: Flu vaccination status is relevant for general health but not critical before golimumab administration. While immunosuppression increases infection risk, tuberculosis screening is more urgent, as TNF inhibitors can reactivate latent TB, posing a severe health threat.

Choice C reason: A recent tuberculosis test is essential, as golimumab suppresses TNF, increasing the risk of reactivating latent TB into active disease. Screening with a tuberculin test or interferon-gamma assay prevents potentially fatal infections, making this the most critical information before starting therapy.

Choice D reason: Oral contraceptive use is unrelated to golimumab’s safety or efficacy. While some drugs interact with contraceptives, golimumab does not, and psoriasis treatment does not involve reproductive considerations, making this choice irrelevant for pre-administration assessment.